Abionyx Pharma Partners With Axplora for CER-001 Manufacturing

• Abionyx Pharma entered a strategic manufacturing partnership with Axplora, completing the production network for its investigational biologic CER-001 alongside Texcell and Olon.
• Axplora will purify recombinant human apoA-I, CER-001's key biological component, at its Pompey site in France.
• The network supports preparations for potential initial marketing authorization in LCAT deficiency, subject to required validations.
• A Phase 2b sepsis trial, RACERS 2, is being prepared following €33 million in financing secured in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abionyx Pharma SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026719139) on October 27, 2026, and is solely responsible for the information contained therein.